menu
    • menu
    [{"orgOrder":0,"company":"Claris Bio","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"Oremepermin Alpha","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Claris Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Claris Bio \/ Organovo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Claris Bio \/ Organovo Holdings"}]

    Find Clinical Drug Pipeline Developments & Deals by Claris Bio

    Menu

    Claris Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Claris Bio

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed

                            Claris Bio

                            U.S.A arrow
                            IMCAS Asia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oremepermin Alpha

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Organovo Holdings

                            Deal Size : $57.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Claris Bio Prepares for Next Stage with New Investor and Late-Stage Data in 2024

                            Details : The net proceeds will be used to advance CSB-001 (oremepermin alfa), a topical ocular biologic solution of dHGF, targets complete healing of the cornea surface in eyes with Neurotrophic Keratopathy.

                            Product Name : CSB-001

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            April 01, 2024

                            Lead Product(s) : Oremepermin Alpha

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Organovo Holdings

                            Deal Size : $57.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth